Parkinson Foundation Centre of Excellence, King's College Hospital and King's College, London, UK.
Parkinson and Movement Disorders Unit, Study Center for Neurodegeneration CESNE, Department of Neuroscience, University of Padova, Padova, Italy.
J Parkinsons Dis. 2022;12(7):2071-2083. doi: 10.3233/JPD-223295.
In advanced Parkinson's disease (PD), dyskinesias and non-motor symptoms such as sleep dysfunction can significantly impair quality of life, and high-quality management is an unmet need.
To analyze changes in dyskinesia and non-motor symptoms (including sleep) among studies with levodopa-carbidopa intestinal gel (LCIG) in patients with advanced PD.
A comprehensive literature review identified relevant studies examining LCIG efficacy. Outcomes of interest were dyskinesia (UDysRS, UPDRS IV item 32), overall non-motor symptoms (NMSS), mentation/behavior/mood (UPDRS I), and sleep/daytime sleepiness (PDSS-2, ESS). The pooled mean (95% confidence interval) change from baseline per outcome was estimated for each 3-month interval with sufficient data (i.e., reported by≥3 studies) up to 24 months using a random-effects model.
Seventeen open-label studies evaluating 1243 patients with advanced PD were included. All outcomes of interest with sufficient data for meta-analysis showed statistically significant improvement within 6 months of starting LCIG. There were statistically significant improvements in dyskinesia duration as measured by UPDRS IV item 32 at 6 months (-1.10 [-1.69, -0.51] h/day) and 12 months (-1.35 [-2.07, -0.62] h/day). There were statistically and clinically significant improvements in non-motor symptoms as measured by NMSS scores at 3 months (-28.71 [-40.26, -17.15] points). Significant reduction of NMSS burden was maintained through 24 months (-17.61 [-21.52, -13.70] points). UPDRS I scores significantly improved at 3 months (-0.39 [-0.55, -0.22] points). Clinically significant improvements in PDSS-2 and ESS scores were observed at 6 and 12 months in individual studies.
Patients with advanced PD receiving LCIG showed significant sustained improvements in the burden of dyskinesia and non-motor symptoms up to 24 months after initiation.
在晚期帕金森病(PD)中,运动障碍和非运动症状(如睡眠功能障碍)可显著降低生活质量,而高质量的管理是未满足的需求。
分析接受左旋多巴-卡比多巴肠凝胶(LCIG)治疗的晚期 PD 患者的运动障碍和非运动症状(包括睡眠)变化。
全面文献回顾确定了评估 LCIG 疗效的相关研究。感兴趣的结局是运动障碍(UDysRS,UPDRS IV 项目 32)、整体非运动症状(NMSS)、精神状态/行为/情绪(UPDRS I)和睡眠/白天嗜睡(PDSS-2、ESS)。使用随机效应模型,根据每个 3 个月的间隔(即报告≥3 项研究)的充足数据,估计从基线开始每个结局的平均(95%置信区间)变化。
纳入了 17 项评估 1243 例晚期 PD 患者的开放性研究。具有足够数据进行荟萃分析的所有感兴趣结局均在开始 LCIG 的 6 个月内显示出统计学显著改善。在 6 个月(-1.10 [-1.69,-0.51] 小时/天)和 12 个月(-1.35 [-2.07,-0.62] 小时/天)时,UPDRS IV 项目 32 测量的运动障碍持续时间有统计学显著改善。在 3 个月时,NMSS 评分测量的非运动症状有统计学和临床显著改善(-28.71 [-40.26,-17.15] 分)。在 24 个月时,NMSS 负担显著减轻(-17.61 [-21.52,-13.70] 分)。在 3 个月时,UPDRS I 评分显著改善(-0.39 [-0.55,-0.22] 分)。在个别研究中,在 6 个月和 12 个月时观察到 PDSS-2 和 ESS 评分的临床显著改善。
接受 LCIG 治疗的晚期 PD 患者在开始治疗后 24 个月内,运动障碍和非运动症状的负担显著持续改善。